Amanta Healthcare IPO GMP Today
In the grey market, the stock is currently trading at an 8% premium over the upper price band of Rs 126, indicating a continued decline in premium — yet still pointing to potential listing gains. The shares are likely to list around Rs 136, offering a Rs 10 premium over the issue price.
Note: The Grey Market Premium (GMP) refers to the unofficial premium at which IPO shares are traded before their official listing. While it can offer insights into market sentiment and potential listing performance, it is neither regulated nor a guaranteed indicator of actual returns.
Amanta Healthcare IPO Subscription Status:
On the third and final day, Amanta Healthcare’s IPO witnessed strong demand, with the overall issue subscribed 23.04 times so far.
Retail Individual Investors (RIIs) led the surge in participation, subscribing to 26.18 times the 35 lakh shares allocated to them, displaying robust interest.Non-Institutional Investors (NIIs), including high-net-worth individuals and corporates, subscribed 47.22 times their reserved quota of 15 lakh shares.In contrast, demand from Qualified Institutional Buyers (QIBs) — such as mutual funds, insurance companies, and foreign institutional investors — was comparatively lower, with only 58% of the 20 lakh shares in their category subscribed.
Amanta Healthcare IPO Details:
Ahmedabad-based Amanta Healthcare is a pharmaceutical company focused on manufacturing sterile liquid formulations and medical devices. The price band for the issue has been set at Rs 120–Rs 126 per share.
The offering comprises a fresh issue of 1 crore equity shares, with the shares expected to be listed on both the BSE and NSE on September 8.
About the Company
Amanta Healthcare specializes in the development and marketing of sterile injectables, IV fluids, ophthalmic solutions, respiratory care products, irrigation solutions, and medical devices. Its key technology platforms include SteriPort (ISBM) and ABFS (Aseptic Blow-Fill-Seal).
The company has established a strong domestic footprint through a network of over 320 distributors and stockists, while also exporting to markets in Africa, Latin America, the UK, and other emerging regions. In FY25, domestic branded generics contributed approximately 55% of total revenue, with international sales accounting for 33%, and the remaining 10% coming from product partnerships and contract manufacturing.
Amanta’s manufacturing facility in Hariyala, Gujarat, houses seven production lines for both Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), and holds certifications from regulatory authorities in India as well as multiple international markets.
Financials
Amanta Healthcare reported consolidated revenue of Rs 274.7 crore in FY25, slightly down from Rs 280.3 crore in FY24. Despite the modest decline in revenue, the company demonstrated a significant improvement in profitability, with profit after tax rising sharply to Rs 10.5 crore in FY25 from Rs 3.6 crore in the previous fiscal year.
IPO Objectives
The company intends to use Rs 70 crore of the IPO proceeds to expand its SteriPort manufacturing line, Rs 30.1 crore to establish a new production line for Small Volume Parenterals (SVPs), with the remaining funds allocated for general corporate purposes.
Should You Subscribe?
Investor4Edu recommends subscribing to the IPO, emphasizing Amanta Healthcare’s strong potential to capitalize on the growing demand for sterile liquid pharmaceuticals and medical devices in both domestic and international markets.
At the upper price band, the stock is valued at approximately 47 times its post-issue FY25 earnings, indicating the IPO is reasonably priced.
With certifications across more than 120 jurisdictions, a diverse product portfolio, and a strategic focus on sterile pharmaceuticals, Amanta Healthcare is well-positioned for sustained growth.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
as a Reliable and Trusted News Source